Emergent BioSolutions Inc. EBS

Company leaders, elected officials and community stakeholders will come together on September 16, 2026 to mark milestone in advanced biopharmaceutical manufacturing CANTON, Mass., Sept. 15, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) will host a ribbon cutting ceremony on Wednesday, September 16 at 10 a.m. ET to celebrate the manufacturing restart and growth of its Canton, Massachusetts facility and the company’s investment in the future of advanced biopharmaceutical manufact

Dublin, Sept. 07, 2026 (GLOBE NEWSWIRE) -- The "Vaccines Market Distribution by Type of Vaccine API, Targeted Patient Population, Type of Vaccines, Route of Administration, and Key Geographical Region - Trends and Forecasts Till 2035" has been added to ResearchAndMarkets.com's offering. The global vaccines market is projected to increase from approximately USD 48 billion to USD 94 billion by 2030, representing a compound annual growth rate of about 11.9% during the forecast period. Market expans

Repurchase reduces unsecured note balance to approximately $364.7 millionManagement to discuss this key milestone and broader transformation progress at upcoming investor conferences GAITHERSBURG, Md., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced that it has completed the repurchase of $75 million aggregate principal amount of its 3.875% Senior Unsecured Notes due 2028 (the “Senior Unsecured Notes”), following authorization granted by its Board of Dir

GAITHERSBURG, Md., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced a contract modification valued at approximately $24 million from the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services (HHS), to supply CYFENDUS® (Anthrax Vaccine Adsorbed, Adjuvanted) for anthrax preparedness efforts. Anthrax remains a significan

Standing offer expands access to opioid overdose emergency treatment across participating federal, provincial and territorial organizations in Canada WINNIPEG, Manitoba, Aug. 31, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced that it has been awarded a standing offer by the Government of Canada, through a competitive procurement process, to supply NARCAN® Nasal Spray. The standing offer is effective from October 1, 2026, through September 30, 2029, with an option

Ready to Rescue campaign returns to U.S. college campuses with Release Recovery Founder and CEO Zac Clark Partnership with professional baseball player Davis Schneider seeks to raise awareness of opioid poisoning preparedness across Canada GAITHERSBURG, Md., Aug. 31, 2026 (GLOBE NEWSWIRE) -- In recognition of International Overdose Awareness Day (IOAD), Emergent BioSolutions (NYSE: EBS) is reaffirming its commitment to expanding awareness of opioid overdose risks and increasing preparedness to h

Shares of Trade Desk, Papa John’s International, Emergent Biosolutions declined after the companies posted disappointing Q2 results last week.

Moby summary of Emergent BioSolutions Inc.'s Q2 2026 earnings call

Second Quarter 2026 Total Revenues of $234.3 million, an improvement of 66% versus prior yearSecond Quarter 2026 Net Loss of $180.2 million worsening 1,402% versus prior year, largely due to a $191.3 million non-cash impairment chargeSecond Quarter 2026 Adjusted Net Income of $30.9 million improved 134% versus prior yearSecond Quarter 2026 Gross Margin % of 50% and Adjusted Gross Margin % of 58%, an expansion of 1400 bps and 900 bps, respectively, versus prior yearSecond Quarter 2026 Adjusted EB

GAITHERSBURG, Md., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions (NYSE:EBS), a global biodefense company, today highlighted the increasing importance of biological threat preparedness as allied nations confront an evolving security environment characterized by geopolitical conflict, artificial intelligence (AI) and synthetic biology and growing concern about the potential misuse of biological agents. Defense and public health leaders are addressing the heightened risks of biological in

GAITHERSBURG, Md., July 22, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) will host a conference call on Wednesday, August 5, 2026, at 5:00 p.m. eastern time to discuss the financial results for the second quarter of 2026. Participants can access the conference call live via webcast and also by visiting the Investors page of Emergent’s website. To participate via telephone, please register in advance at this link. Upon registration, all telephone participants will receive a con

Erste Group Bank stock has delivered a very strong 384.0% return over the past 5 years, while the current valuation checks send a more mixed message, with the intrinsic value estimate from the Excess Returns model pointing to upside and the market multiples suggesting the shares are closer to fairly priced. A 384.0% 5 year return puts Erste Group Bank firmly in the group of stocks where past gains are large enough that valuation now matters a lot for what happens next. For a bank like Erste...

GAITHERSBURG, Md., June 29, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions (NYSE:EBS) today announced it has been awarded a contract modification valued at $52.7 million from the Administration for Strategic Preparedness and Response (ASPR) at the United States Department of Health and Human Services to supply ACAM2000® (Smallpox and Mpox (Vaccinia) Vaccine, Live) vaccine, ancillaries as well as diluent replacement lots for smallpox preparedness and response needs. Deliveries are expected to beg

Efforts focus on increasing awareness, expanding access to lifesaving NARCAN® Nasal Spray and reaching more communities with educational initiatives and resourcesGAITHERSBURG, Md., June 04, 2026 (GLOBE NEWSWIRE) -- In honor of National Naloxone Awareness Day on June 6th, Emergent BioSolutions Inc. (NYSE: EBS) is teaming up with Victoria’s Voice Foundation – which launched the awareness day with bipartisan congressional support – to spread awareness and encourage action against the ongoing opioid